$NWBO Headlines Inovio responds to Mr. Feuerst
Post# of 144502
Inovio responds to Mr. Feuerstein's article 10:17 a.m. June 11, 2014 - Seeking Alpha
7 Biotechnology Stocks to Buy Now 5:45 a.m. June 11, 2014 - InvestorPlace.com
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition 10:32 a.m. June 6, 2014 - TheStreet.com
11 Best Cheap Stocks Under $10 to Buy Now 5:45 a.m. June 6, 2014 - InvestorPlace.com
Northwest Bio Fuzzier on Cancer Vaccine Study Patient Enrollment 8:30 a.m. June 5, 2014 - TheStreet.com
The Case Of Northwest Biotherapeutics' Missing DMC Recommendation 12:25 p.m. June 4, 2014 - Seeking Alpha
7 Biotechnology Stocks to Buy Now 5:15 a.m. June 4, 2014 - InvestorPlace.com
Northwest Biotherapeutics: Academic Results Create Positive Risk/Reward 3:05 p.m. June 2, 2014 - Seeking Alpha
If You Build It, They Will Chuckle: Northwest Bio's Super-Sized ASCO '14 Booth 11:23 a.m. June 2, 2014 - TheStreet.com
Celldex: The Race Leader In Glioblastoma Multiforme 3:17 p.m. May 29, 2014 - Seeking Alpha
Northwest vs Feuerstein rhubarb round 4 10:04 a.m. May 29, 2014 - Seeking Alpha
The Seven Deadly Sins of Biotech Investing 7:00 a.m. May 29, 2014 - TheStreet.com
'Mad Money' Lightning Round: Take Palo Alto Networks Over FireEye 6:00 a.m. May 29, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Plan for the Worst, Hope for the Best 8:04 p.m. May 28, 2014 - TheStreet.com
Northwest Biotherapeutics: Management Discusses Interim Data On Phase I/II Trial Of DCVax-Direct 5:13 p.m. May 28, 2014 - Seeking Alpha
7 Biotechnology Stocks to Buy Now 6:00 a.m. May 28, 2014 - InvestorPlace.com
Cancer Patients Aren't Responding to Northwest Bio's DCVax-Direct 6:07 p.m. May 27, 2014 - TheStreet.com
7 Biotechnology Stocks to Buy Now 6:00 a.m. May 21, 2014 - InvestorPlace.com
Northwest Biotherapeutics Reports On Sarcoma Patient Treated With DCVAx-Direct 10:43 a.m. May 15, 2014 - Seeking Alpha
Northwest Bio Exploits Cancer Patient To Promote Stock Ahead of ASCO '14 9:30 a.m. May 15, 2014 - TheStreet.com
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics 5:30 a.m. Today - PR Newswire - PRF
NW BIO NAMED TO TWO RUSSELL INDEXES 8:15 a.m. June 16, 2014 - PR Newswire - PRF
DCVAX®-L PHASE III TRIAL INITIATED IN GERMANY 8:15 a.m. June 10, 2014 - PR Newswire - PRF
MarketExclusive.com - SummerStreet Research Partners Reiterates Buy Rating of Northwest Biotherapeutics, Inc. 2:24 p.m. June 4, 2014 - ACCESSWIRE
NW BIO TO PRESENT AT JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE 11:23 a.m. June 4, 2014 - PR Newswire - PRF
Pre-clinical Trial Results, Expanded Studies, Preliminary Data Release, and Leadership Appointments - Analyst Notes on Alnylam, BioCryst, Puma Biotechnology, Intrexon and NW Bio 5:40 a.m. May 30, 2014 - PR Newswire - PRF
NW BIO REFUTES MORE FALSE CLAIMS BY FEUERSTEIN 9:27 a.m. May 29, 2014 - PR Newswire - PRF
Pharmaceutical Development & Medical Cannabis Expand at an Aggressive Rate - Company Attracts Major Attention at WebCongress Conference in San Francisco 9:20 a.m. May 16, 2014 - PR Newswire - PRF
NW BIO ANNOUNCES FIRST DATA FROM ONGOING DCVAX-DIRECT TRIAL 8:00 a.m. May 15, 2014 - PR Newswire - PRF
Top Gainers Technical Data -- Research on Northwest Biotherapeutics, Midstates Petroleum, AVEO Pharma, and Infinity Pharma 8:21 a.m. May 12, 2014 - PR Newswire - PRF
PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING 8:15 a.m. April 22, 2014 - PR Newswire - PRF
NW BIO ANNOUNCES FINANCING OF UP TO $32 MILLION 8:15 a.m. April 10, 2014 - PR Newswire - PRF
NW BIO AGAIN SETS FEUERSTEIN RECORD STRAIGHT 8:15 a.m. April 7, 2014 - PR Newswire - PRF
NW BIO REFUTES FURTHER FALSE AND MISLEADING CLAIMS BY FEUERSTEIN 1:03 p.m. March 28, 2014 - PR Newswire - PRF
Technical Insight on Top Gainers -- Research on Signet Jewelers, Quicksilver Resources, Northwest Biotherapeutics, and Goodrich Petroleum 11:00 a.m. March 28, 2014 - PR Newswire - PRF
Northwest Biotherapeutics To Present At The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference 8:15 a.m. March 27, 2014 - PR Newswire - PRF
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics 8:20 a.m. March 13, 2014 - PR Newswire - PRF
NW Bio Refutes False Claims By Adam Feuerstein 9:59 a.m. March 12, 2014 - PR Newswire - PRF
NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement 8:00 a.m. March 10, 2014 - PR Newswire - PRF
NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review 9:00 a.m. March 7, 2014 - PR Newswire - PRF